Medicenna Therapeutics welcomes Dr. Jack Geltosky to its Board of Directors

– CANADA, Toronto –  Medicenna Therapeutics Corp. (NASDAQ: MDNA | TSX: MDNA), a clinical-stage immuno-oncology company, today announced the appointment of Dr. Jack Geltosky to its Board of Directors.

“We are thrilled to be strengthening our Board with the appointment of Dr. Geltosky,” said CEO, Dr. Fahar Merchant. “His extensive management and business development experience will be an invaluable asset as we work to ensure Medicenna’s continued success. On behalf of Medicenna’s leadership, I would like to welcome Jack to our team and also extend our thanks to Mr. Andrew Strong for four years of distinguished service.”

About Dr. Jack Geltosky

Dr. Jack Geltosky is an experienced pharmaceutical licensing executive with a strong R&D background. He has extensive commercial development and deal portfolio from his role as Vice President External Science, Technology & Licensing at Bristol Myers Squibb as well as Vice President, Scientific Licensing, Worldwide Business Development at SmithKline Beecham. Dr. Geltosky also held roles of increasing responsibility within Johnson & Johnson over a 10-year period. He began his career as a research scientist at E.I. DuPont. Dr. Geltosky is currently the Chairman of the Product Development Review Council for Cancer Prevention and Research Institute of Texas, and previously served as Senior Vice President of Business Development, Life Science at Arizona Technology Enterprises. Jack is currently Managing Director of JEG and Associates, LLC, a business development consultancy firm focused on biotech and pharmaceuticals.

Dr. Geltosky added, “Joining Medicenna’s board is a truly exciting opportunity. The best in class potential of the Company’s MDNA11 IL-2 super-agonist, combined with MDNA55’s compelling Phase 2 data package in recurrent glioblastoma, leave Medicenna well-positioned to achieve near-term milestones and sustained growth. I look forward to working closely with Medicenna’s Board and management team to advance the Company’s pipeline of engineered interleukins and address unmet medical needs.”

He holds a Ph.D. in biochemistry from the California Institute of Technology.

About Medicenna

Medicenna is a clinical-stage immunotherapy company focused on the development of novel, highly selective versions of IL-2, IL-4 and IL-13 Superkines and first in class Empowered Cytokines for the treatment of a broad range of cancers. Medicenna’s long-acting IL2 Superkine asset, MDNA11, is potentially a best-in-class next-generation IL-2 with superior CD122 binding without CD25 affinity and therefore preferentially stimulating cancer-killing effector T cells and NK cells when compared to competing IL-2 programs. It is anticipated that MDNA11 will be ready for the clinic in 2021. Medicenna’s lead IL4-EC, MDNA55, has completed a Phase 2b clinical trial for recurrent glioblastoma, the most common and uniformly fatal form of brain cancer. MDNA55 has been studied in five clinical trials involving 132 patients, including 112 adults with rGBM. MDNA55 has demonstrated compelling efficacy and has obtained Fast-Track and Orphan Drug status from the FDA and FDA/EMA, respectively.

For more information: https://www.medicenna.com/

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.

Talent4Boards Team

here the original post =>